. Author manuscript; available in PMC: 2011 Nov 1.

Published in final edited form as: Nat Rev Clin Oncol. 2010 Sep 14;7(11):653–664. doi: 10.1038/nrclinonc.2010.139

Table 1.

Nanoparticle formulations for the treatment of solid tumors^*

Generic name	Trade name(s)	Indication	Benefit
Pegylated liposomal doxorubicin	Doxil^® and Caelyx^®	Hiv-related Kaposi’s sarcoma	No statistically significant change in overall survival (23 weeks) vs doxorubicin, bleomycin and vincristine treatment (22.3 weeks) for Hiv-related Kaposi’s sarcoma¹⁴⁴
		Metastatic ovarian cancer	Statistically significant overall survival improvement (108 weeks, P = 0.008) vs topotecan treatment (71.1 weeks) for platinum-sensitive patients with ovarian cancer¹⁴
		Metastatic breast cancer	No statistically significant overall survival change (84 weeks) vs conventional doxorubicin (88 weeks) for breast cancer patients receiving first-line therapy¹⁴⁵

Liposomal daunorubicin	DaunoXome^®	Hiv-related Kaposi’s sarcoma	No statistically significant overall survival change (52.7 weeks) vs doxorubicin, bleomycin and vincristine treatment (48.9 weeks)¹⁴⁶

Albumin-bound paclitaxel	Abraxane^®	Metastatic breast cancer	Statistically significant overall survival change (56.4 weeks, P = 0.024) vs polyethylated castor oil-based paclitaxel treatment (46.7 weeks) for patients receiving second-line treatment⁷

The polymeric platform methoxy-PEG-poly(d,l-lactide) taxol with the trade name Genexol-PM (Samyang Co., Seoul, Korea) has been approved in Korea for the treatment of metastatic breast cancer.¹⁴⁷,¹⁴⁸